Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is a clinical-stage biotech company with a strong focus on effective CNS drug delivery. Their lead products, NEO100 and NEO212, have shown promising results and have the potential for accelerated approval, with further research ongoing for hard-to-treat brain tumors. The company has secured funding for continued operations and management has a positive outlook on the success of these drugs.

Bears say

NeOnc Technologies Hldgs is facing several fundamental challenges that negatively impact the outlook for its stock. Firstly, the company's drug delivery method and lead product candidates, while promising, have significant technical and safety risks that may limit their effectiveness and potential application to certain types of brain tumors. Secondly, the company's financials and patent portfolio are not strong enough to overcome these challenges and successfully bring its products to market. Finally, the company's leadership team lacks the necessary experience in the biopharmaceutical industry, and their past successes may not translate to the complex and competitive field of CNS diseases.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.